Discreet: Take your medication anytime, anywhere without drawing attention
Clinical Evidence on GLP-1 Therapy and Blood Pressure Outcomes The SUSTAIN trials, large randomized controlled studies of semaglutide in type 2 diabetes, documented systolic blood pressure reductions of 35 mmHg compared to placebo, with some participants experiencing drops exceeding 10 mmHg
[170] [171] In June 2025, the European Medicines Agency recommended that the product information for semaglutide medicines be updated to include non-arteritic anterior ischemic optic neuropathy (NAION) as a very rare side effect, [172] while the World Health Organization concluded that the risk management plan for semaglutide should be revised to include NAION as a potential risk
Monitor the injection site for reactions
When bloating, gas, or discomfort persist, tracking can add another layer of clarity by helping you see how digestion may be changing over time